BDBM516962 N-(4-((3-((1,3-dihydroxy-2-methylpropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide::US11104676, Example 32

SMILES CC(CO)(CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4ccnn(-c5ccc(F)cc5)c4=O)cc3F)c12

InChI Key InChIKey=CTPHZJUGWFVHAY-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 516962   

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 2.20E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 5.70E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 3.73E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 3.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 7.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 9.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 5.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 4.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 102nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 3.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 5.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM516962(US11104676, Example 32 | N-(4-((3-((1,3-dihydroxy-...)
Affinity DataIC50: 3.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent